This study examined annual utilization trends of breast, cervical, and colorectal cancer screening among commercially insured enrollees in the United States from 2010 through 2019. The authors note that screening guidelines for these cancers changed substantially across the decade; the analysis focused on observed annual test use rather than guideline-concordant, up-to-date screening status.
The investigation used administrative claims to estimate the proportion of eligible enrollees who received each screening test within each calendar year, stratified by age group, screening modality, and geographic residence.
Design and data source: The investigators conducted a retrospective, serial cross-sectional analysis of the Merative (formerly IBM Watson Health) MarketScan Commercial Claims and Encounters Database for 2010–2019. The analytic sample represented approximately 141.2 million privately insured enrollees over the study period.
Outcome definitions: Annual screening rates were defined as the proportion of eligible enrollees receiving the relevant procedure codes for cervical, breast, or colorectal cancer screening within a given calendar year. These annual rates measure utilization within a year rather than whether an individual was up to date with guideline-recommended intervals.
Stratification and comparisons: Results were stratified by age group, screening modality (for example, cervical cytology alone versus co-testing), and geographic region including urban versus rural residence.
Statistical analysis: Temporal trends across 2010–2019 were evaluated using two-sided Poisson regression. Urban–rural disparities in 2019 were assessed with multivariate generalized estimating equations. The manuscript reports incidence rate ratios for urban versus rural comparisons in 2019.
Cervical screening utilization changed notably in modality composition over the study period. Among women aged 30–64 years, the annual proportion receiving cervical cytology alone declined substantially from 28.2% in 2010 to 8.8% in 2019. By contrast, co-testing (cytology plus HPV testing) increased from 11.4% in 2010 to 20.3% in 2019. These shifts reflect changing practice patterns in the use of HPV testing and combined screening modalities during the decade.
The reported rates represent yearly testing events among eligible enrollees, and the analysis did not present measures of up-to-date status according to specific guideline intervals.
Screening mammography utilization among the commercially insured subgroup examined was essentially unchanged across the decade. For women aged 50–64 years, the annual screening mammography rate was 45.7% in 2010 and 45.8% in 2019, indicating minimal net change in annual utilization across this age band.
No additional subgroup-specific mammography changes or modality shifts beyond the reported age-group rates were described in the source.
Annual colorectal cancer screening utilization among enrollees aged under 64 years decreased modestly over the study period, from 7.7% in 2010 to 6.5% in 2019. The decline was more pronounced in the 45–49-year-old age group, although detailed subgroup percentages beyond that general statement were not reported in the source text.
As with other outcomes, these estimates reflect annual receipt of screening tests identified in claims data rather than guideline-based up-to-date screening coverage.
Across breast, cervical, and colorectal cancer screenings, utilization in 2019 was higher among urban residents compared with rural residents. The reported incidence rate ratios for urban versus rural screening utilization in 2019 ranged approximately from 1.02 to 1.05, indicating modest but consistent urban advantage in annual screening rates.
The authors used multivariate generalized estimating equations to adjust comparisons, but the source does not provide the full list of covariates or the tabulated adjusted estimates in the abstract.
Among commercially insured adults from 2010 to 2019, annual utilization of cervical, breast, and colorectal cancer screening did not improve and in some cases declined. Notable findings included a marked shift from cervical cytology alone toward increased co-testing, steady low-to-moderate mammography annual utilization among women 50–64, and a modest decline in colorectal screening with a sharper decrease among adults aged 45–49.
Persistent urban–rural disparities in screening utilization in 2019 were observed, suggesting ongoing gaps in delivery of preventive services that may disproportionately affect rural and underserved populations. The authors conclude that targeted interventions could be needed to increase screening utilization, particularly in rural settings.
Data source and sharing: The underlying data are from the Merative MarketScan Commercial Claims and Encounters Database; data cannot be shared publicly because of data use agreement restrictions and licensing limitations. MarketScan data are available for licensing from Merative.
Ethical oversight and reporting: The Institutional Review Board of Johns Hopkins Bloomberg School of Public Health waived ethical approval for this work. The authors declared no competing interests. The source indicates compliance with relevant reporting guidelines.
Note: This summary reports findings exactly as described in the source preprint abstract and metadata. The source provides limited tabular detail in the abstract; additional subgroup estimates, covariate lists for adjusted models, and full statistical outputs were not reported in the abstract and are not available here.